Home » Product Type » Toxins » Conantokin-T

Conantokin-T

Cat. No. 3122

Price and Availability

For Conantokin-T pricing & availability please select your country from the drop down menu:
Submit

By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Biological Activity

Non-competitive NMDA receptor antagonist (IC₅₀ = 0.4 μM). Inhibits Ca²⁺ influx and glutamate-induced toxicity in central nervous system neurons. Exhibits age-dependent physiological effects; induces a sleep-like state in young mice and hyperactivity in older mice.

Licensing Information

Sold under license from University of Utah

Technical Data

M.Wt:

2683.8

Formula:

C₁₁₀H₁₇₅N₃₁O₄₅S

Sequence:

GEXXYQKMLXNLRXAEVKKNA

(Modifications: X = Gla, Ala-21 = C-terminal amide)

Storage:

Store at -20°C

CAS No:

127476-26-0

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Resources

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch

Safety Data Sheet: View Safety Data Sheet

References

Haack et al (1990) Conantokin-T. J.Biol.Chem. 265 6025. PMID: 2180939.

Klein et al (1999) Inhibition of NMDA-induced currents by conantokin-G and conantokin-T in cultured embryonic murine hippocampal neurons. Neuropharmacology 38 1819. PMID: 10608277.

Warder et al (2001) Amino acid determinants for NMDA receptor inhibition by conantokin-T. J.Neurochem. 77 812. PMID: 11331410.

If you know of a relevant citation for this product please let us know.

View Related Products by Target

Glutamate (Ionotropic) Receptors

NMDA Receptors

Keywords: Conantokin-T, supplier, Non-competitive, NMDA, receptor, antagonists, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic

Quick Order

Find multiple products by catalog number

Pain Research Product Guide

Highlights over 280 products for Pain research. Request copy or view PDF today.

Therapeutic Strategies in Schizophrenia

Written by J. Lieberman

'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.

Calcium Imbalance and Neuroprotective Targets

Written by E. Besancon et al

'Calcium Imbalance and Neuro-protective Targets in Cerebral Ischemia & Brain Injury' highlights the key targets involved in stroke, trauma and neurodegeneration.

Neurobiology of Parkinson's Disease

Written by A. Schapira

'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.